PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 27, 2018New England Journal of Medicine78 citations

Metastasis-free Survival — A New End Point in Prostate Cancer Trials

View Full Paper
JBJulia A. BeaverPKPaul G. KluetzRPRichard Pazdur

Key Points

Key points are not available for this paper at this time.

Abstract

The FDA’s approval of apalutamide for use in nonmetastatic castration-resistant prostate cancer (nmCRPC) was based on an improvement in metastasis-free survival. It was the first drug approval for nmCRPC and the first use of this primary end point to support drug approval.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Beaver et al. (2018) studied this question.

synapsesocial.com/papers/6a03e78e4a5db22ff2893c30https://doi.org/10.1056/nejmp1805966
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer2005 · 499 citations
  2. 2Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model2015 · 245 citations
  3. 3Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer2018 · 1,353 citations
  4. 4Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time2013 · 250 citations
  5. 5Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group2008 · 2,264 citations